Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3575-3581

  Deacon, Carolyn F ^a   Nauck, Michael A ^b   Meier, Juris ^c   Hücking, Katrin ^c   Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ST JOSEF HOSPITAL   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE;

ADULT; AMINO TERMINAL SEQUENCE; AREA UNDER THE CURVE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; IMMUNOREACTIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN METABOLISM; RADIOIMMUNOASSAY;

EID: 0033766716     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.10.3575     Document Type: Article

References (35)

1. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat
2. New developments in the incretin concept
3. Glucagon-like peptide 17-36: A physiological incretin in man
4. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
5. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo
6. Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV
7. Glucagon-like peptide-I analogs: Effects on insulin secretion and adenosine 3',5'-monophosphate formation
8. Structure-activity studies of glucagon-like peptide-1
9. Amino acid sequence and hetergeneity of gastric inhibitory polypeptide (GIP)
10. Actions of GIP
11. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
12. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach
13. The enteroinsular axis in dipeptidyl peptidase IV-negative rats
14. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics
15. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
16. Synthetic peptides as antigen
17. Pancreatic and intestinal processing of proglucagon in man
18. 2-terminus in type II diabetic patients and in healthy subjects
19. Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig
20. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
21. The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man
22. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8
23. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day
24. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides
25. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36amide) concentrations and improves oral glucose tolerance in obese Zucker rats
26. Chronic renal failure: Effect of hemodialysis on gastrointestinal hormones
27. Renal effects on serum gastric inhibitory polypeptide (GIP)
28. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats
29. The hepatic extraction of gastric inhibitory polypeptide and insulin
30. Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs
31. Glomerular filtration rate and kidney size in type 2 (non-insulin-dependent) diabetes mellitus
32. Glomerular hyperfiltration in microalbuminuric NIDDM patients
33. Current concepts of renal hemodynamics in diabetes
34. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects
35. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus